Literature DB >> 2674417

Effects of endothelin on regional blood flows in squirrel monkeys.

M Clozel1, J P Clozel.   

Abstract

Endothelin is a newly described potent vasoconstrictor produced by endothelial cells. The aim of the present study was to evaluate the effects of i.v. injection of human endothelin on regional blood flows (RBFs) and hemodynamic parameters in nonhuman primates. For this purpose, in a first series of experiments, anesthetized squirrel monkeys were instrumented with Doppler flow-probes in order to measure RBF continuously in the renal, mesenteric and iliac vascular beds. Endothelin at 0.03 and 0.1 microgram/kg produced no effect. After 0.3 and 1 microgram/kg, renal and mesenteric blood flow decreased, but iliac blood flow increased transiently. With 3 micrograms/kg all the three vascular beds were constricted. In the kidney, blood flow was almost abolished and the effect of endothelin sustained for up to 2 hr and more. In a second series of experiments, radioactive microspheres were used to measure RBFs in most organs 3 to 4 min after endothelin (0.3, 1 and 3 microgram/kg), or after vehicle alone. Endothelin induced a dose-dependent increase in systemic vascular resistance and increase in mean arterial blood pressure. The vasoconstrictor effect was selective for some vascular beds. The splanchnic vascular bed (except stomach) was most affected, with a 96% decrease in renal and splenic blood flow after 3 micrograms/kg of endothelin. The coronary blood flow decreased by 46% after 3 micrograms/kg, with a greater effect in subepicardium than subendocardium. In contrast, the blood flow to the brain and stomach was not decreased by endothelin. We conclude that endothelin is a potent vasoconstrictor in squirrel monkeys selective for some vascular beds.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2674417

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  14 in total

Review 1.  Therapeutic role of bosentan in hypertension: lessons from the model of perinephritic hypertension.

Authors:  J E Donckier
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

Review 2.  [Therapy of pulmonary arterial hypertension].

Authors:  R Voswinckel; F Reichenberger; H Gall; W Seeger; F Grimminger; H A Ghofrani
Journal:  Internist (Berl)       Date:  2009-09       Impact factor: 0.743

Review 3.  Regulation of blood pressure and salt homeostasis by endothelin.

Authors:  Donald E Kohan; Noreen F Rossi; Edward W Inscho; David M Pollock
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

Review 4.  ET-1 actions in the kidney: evidence for sex differences.

Authors:  W Kittikulsuth; J C Sullivan; D M Pollock
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

5.  Functional heterogeneity of NADPH oxidase-mediated contractions to endothelin with vascular aging.

Authors:  Matthias R Meyer; Matthias Barton; Eric R Prossnitz
Journal:  Life Sci       Date:  2013-12-29       Impact factor: 5.037

Review 6.  Endothelin and the renal microcirculation.

Authors:  Zhengrong Guan; Justin P VanBeusecum; Edward W Inscho
Journal:  Semin Nephrol       Date:  2015-03       Impact factor: 5.299

7.  Endothelin-1 is a candidate mediating intestinal dysmotility in patients with acute pancreatitis.

Authors:  C Y Chen; C L Lu; F Y Chang; R H Lu; W W Ng; S D Lee
Journal:  Dig Dis Sci       Date:  1999-05       Impact factor: 3.199

Review 8.  Endothelin in heart failure.

Authors:  G Sütsch; M Barton
Journal:  Curr Hypertens Rep       Date:  1999 Feb-Mar       Impact factor: 5.369

9.  Ovarian hormones modulate endothelin A and B receptor expression.

Authors:  Eman Y Gohar; Choudhury Yusuf; David M Pollock
Journal:  Life Sci       Date:  2016-01-08       Impact factor: 5.037

10.  Phosphoramidon blocks big-endothelin-1 but not endothelin-1 enhancement of vascular permeability in the rat.

Authors:  S Lehoux; G E Plante; M G Sirois; P Sirois; P D'Orléans-Juste
Journal:  Br J Pharmacol       Date:  1992-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.